Altimmune, Inc. (ALT) DCF Valuation

Altimmune, Inc. (ALT) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Altimmune, Inc. (ALT) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Whether you’re an investor or analyst, this (ALT) DCF Calculator is your go-to resource for accurate valuation. Equipped with real data from Altimmune, Inc., you can adjust forecasts and observe the effects in real-time.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 5.8 8.2 4.4 -.1 .4 .2 .1 .0 .0 .0
Revenue Growth, % 0 41.09 -46.12 -101.54 -726.47 -51.26 -51.26 -51.26 -51.26 -51.26
EBITDA -20.2 -54.2 -96.5 -84.4 -87.9 -.1 -.1 .0 .0 .0
EBITDA, % -348 -661.62 -2188.8 124120.59 -20642.02 -60 -60 -60 -60 -60
Depreciation .4 .3 .6 .5 .5 .0 .0 .0 .0 .0
Depreciation, % 6.68 3.64 12.5 -735.29 111.97 4.56 4.56 4.56 4.56 4.56
EBIT -20.6 -54.5 -97.1 -84.9 -88.4 -.1 -.1 .0 .0 .0
EBIT, % -354.68 -665.26 -2201.3 124855.88 -20753.99 -60 -60 -60 -60 -60
Total Cash 37.2 215.9 190.3 184.9 197.8 .1 .1 .0 .0 .0
Total Cash, percent .0 .0 .0 -.3 .0 .0 .0 .0 .0 .0
Account Receivables 1.7 12.4 .4 2.5 4.9
Account Receivables, % 28.45 151.17 9.73 -3736.76 1139.2
Inventories -503.9 -1,958.9 -13,388.5 .0 .0 -.1 -.1 .0 .0 .0
Inventories, % -8685.79 -23932.58 -303569.96 -50 0 -70 -70 -70 -70 -70
Accounts Payable .0 .6 2.0 4.8 2.1 .0 .0 .0 .0 .0
Accounts Payable, % 0.31427 7.48 46.12 -7064.71 485.92 10.78 10.78 10.78 10.78 10.78
Capital Expenditure .0 -.3 -12.3 -.1 .0 .0 .0 .0 .0 .0
Capital Expenditure, % -0.49986 -4.18 -279.15 185.29 -11.03 -23.14 -23.14 -23.14 -23.14 -23.14
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -20.5 -49.0 -96.2 -84.7 -88.4 -.1 -.1 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF 482.1 1,395.8 11,335.1 -13,472.2 -93.0 2.7 -.1 -.1 .0 .0
WACC, % 5.39 5.39 5.39 5.39 5.39 5.39 5.39 5.39 5.39 5.39
PV UFCF
SUM PV UFCF 2.4
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value 2
Net Debt -134
Equity Value 136
Diluted Shares Outstanding, MM 53
Equity Value Per Share 2.56

What You Will Get

  • Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to explore various scenarios.
  • Real-World Data: Pre-filled financial data for Altimmune, Inc. (ALT) to kickstart your analysis.
  • Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
  • Customizable and Professional: A refined Excel model tailored to your valuation requirements.
  • Built for Analysts and Investors: Perfect for evaluating projections, validating strategies, and enhancing efficiency.

Key Features

  • Comprehensive ALT Data: Pre-filled with Altimmune’s historical financials and future projections.
  • Fully Customizable Inputs: Adjust revenue growth, profit margins, discount rates, tax rates, and capital expenditures.
  • Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your inputs.
  • Scenario Testing: Create multiple forecast scenarios to evaluate different valuation outcomes.
  • User-Friendly Design: Simple, structured, and tailored for both professionals and beginners.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered Altimmune data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for Altimmune’s intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose Altimmune, Inc. (ALT) Calculator?

  • Save Time: Quickly access a pre-built DCF model tailored for Altimmune, Inc. (ALT) without starting from scratch.
  • Enhance Precision: Utilize accurate financial data and formulas to minimize valuation errors.
  • Fully Customizable: Adjust the model to align with your specific assumptions and forecasts regarding Altimmune, Inc. (ALT).
  • User-Friendly: Intuitive charts and outputs simplify the analysis of results.
  • Endorsed by Professionals: Crafted for experts who prioritize accuracy and functionality in their evaluations.

Who Should Use This Product?

  • Investors: Accurately assess Altimmune, Inc.'s (ALT) fair value prior to making investment choices.
  • CFOs: Utilize a professional-grade DCF model for financial reporting and analysis tailored to Altimmune, Inc. (ALT).
  • Consultants: Efficiently modify the template for valuation reports concerning Altimmune, Inc. (ALT) for clients.
  • Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms.
  • Educators: Implement it as a teaching resource to illustrate valuation methodologies in the biotech sector.

What the Template Contains

  • Pre-Filled Data: Includes Altimmune, Inc.'s historical financials and forecasts.
  • Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
  • Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
  • Key Financial Ratios: Analyze Altimmune, Inc.'s profitability, efficiency, and leverage.
  • Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
  • Clear Dashboard: Charts and tables summarizing key valuation results.

Es wurden keine passenden Produkte gefunden.